Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,124 | 1,786 | 2,130 | 4,175 | 2,094 |
| Marketable Securities | 7,556 | 9,726 | 11,769 | 15,152 | 20,422 |
| Receivables | 341 | 568 | 825 | 1,151 | 614 |
| Other current assets | 765 | 754 | 0 | 0 | 0 |
| TOTAL | $9,786 | $12,834 | $14,724 | $20,478 | $23,130 |
| Non-Current Assets | |||||
| PPE Net | 97 | 105 | 114 | 122 | 130 |
| Investments And Advances | 3,265 | 1,676 | 1,500 | 0 | 0 |
| Other Non-Current Assets | 129 | 176 | 223 | 269 | 315 |
| TOTAL | $3,491 | $1,957 | $1,837 | $391 | $445 |
| Total Assets | $13,277 | $14,791 | $16,561 | $20,869 | $23,575 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,723 | 2,801 | 3,094 | 5,031 | 2,729 |
| TOTAL | $2,723 | $2,801 | $3,094 | $5,031 | $2,729 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 44 | 0 | 0 |
| TOTAL | $N/A | $N/A | $44 | $89 | $134 |
| Total Liabilities | $2,723 | $2,801 | $3,138 | $5,120 | $2,863 |
| Shareholders' Equity | |||||
| Common Shares | 70 | 70 | 70 | 70 | 70 |
| Retained earnings | -189,463 | -187,870 | -186,040 | -183,401 | -178,051 |
| Other shareholders' equity | -662 | -645 | -745 | -876 | -982 |
| TOTAL | $10,554 | $11,990 | $13,423 | $15,749 | $20,712 |
| Total Liabilities And Equity | $13,277 | $14,791 | $16,561 | $20,869 | $23,575 |